Second-line Surufatinib Combined With Chemotherapy in Advanced CRC
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A phase II, muti-cohort study to assess the efficacy and safety of Surufatinib combined with
chemotherapy as a second-line treatment in patients with advanced CRC